{
    "2019-12-06": [
        [
            {
                "time": "2018-03-15",
                "original_text": "Are more good times ahead for M&A?",
                "features": {
                    "keywords": [
                        "M&A",
                        "good times"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "finance"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2019-06-24",
                "original_text": "Biogen Up on New Data on Alzheimer's Candidate Aducanumab",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Alzheimer's",
                        "Aducanumab",
                        "New Data"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-07-10",
                "original_text": "Regeneron Reports Positive Data on Rare Blood Disorder Drug",
                "features": {
                    "keywords": [
                        "Regeneron",
                        "Positive Data",
                        "Rare Blood Disorder"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-08-12",
                "original_text": "Is Biogen Stock A Buy After Rocketing On A New Analysis In Alzheimer's?",
                "features": {
                    "keywords": [
                        "Biogen",
                        "Stock",
                        "Buy",
                        "Rocketing",
                        "Alzheimer's"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-12-03",
                "original_text": "The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend",
                "features": {
                    "keywords": [
                        "Cassava",
                        "Gains",
                        "Alzheimer's",
                        "Bristol-Myers",
                        "Dividend"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2019-09-25",
                "original_text": "Swiss approve insurance cover for Novartis, Gilead cell therapies",
                "features": {
                    "keywords": [
                        "Swiss",
                        "approve",
                        "insurance",
                        "Novartis",
                        "Gilead",
                        "cell therapies"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}